

Remarks

Applicants respectfully submit that no new prohibited matter has been introduced by this Preliminary Amendment. While written description support for the claims can be found throughout the specification, examples of specific support for the additional claims can be found in the specification as set forth in the table below.

Claim	Support in Specification
28-32	original claims 1, 3 & 7; page 30, line 29
34-41	page 29, lines 8-9
42-48	page 22, lines 18-22; page 23, lines 12-14


Restriction Requirement Under 35 U.S.C. 121

In response to the Restriction Requirement dated September 6, 2002 (Paper No. 11), the period for response having been extended from October 6, 2002 to November 6, 2002 by payment of a one-month extension of time, **Applicants hereby elect to prosecute the claims of Group I (claim 7) drawn to a BRCA1 gene not associated with breast or ovarian cancer.** Applicants further submit that the additional claims submitted with this amendment correspond to original claim 7 and constitute a single invention for examination purposes.

Except for issues payable under 37 C.F.R. 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a **constructive petition for extension of time** in accordance with 37 C.F.R. 1.136(a)(3).

Dated: **November 6, 2002**
Morgan, Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
202-739-3000

Respectfully submitted
Morgan, Lewis & Bockius LLP



Robert Smyth
Registration No. 50,801